Considering statins for cholesterol-reduction in children if lifestyle and diet changes do not improve their health: a review of the risks and benefits.

Hdl Handle:
http://hdl.handle.net/10147/135096
Title:
Considering statins for cholesterol-reduction in children if lifestyle and diet changes do not improve their health: a review of the risks and benefits.
Authors:
O'Gorman, Clodagh S M; O'Neill, Michael B; Conwell, Louise S
Affiliation:
Graduate Entry Medical School, University of Limerick, Ireland, and Mid-Western Regional Hospital, Limerick, Ireland. clodagh.ogorman@ul.ie
Citation:
Considering statins for cholesterol-reduction in children if lifestyle and diet changes do not improve their health: a review of the risks and benefits. 2010, 7:1-14 Vasc Health Risk Manag
Journal:
Vascular health and risk management
Issue Date:
Dec-2010
URI:
http://hdl.handle.net/10147/135096
DOI:
10.2147/VHRM.S7356
PubMed ID:
21339908
Additional Links:
http://www.ncbi.nlm.nih.gov/pubmed/21339908
Abstract:
Children who appear healthy, even if they have one or more recognized cardiovascular risk factors, do not generally have outcomes of cardiovascular or other vascular disease during childhood. Historically, pediatric medicine has not aggressively screened for or treated cardiovascular risk factors in otherwise healthy children. However, studies such as the P-Day Study (Pathobiological Determinants of Atherosclerosis in Youth), and the Bogalusa Heart Study, indicate that healthy children at remarkably young ages can have evidence of significant atherosclerosis. With the increasing prevalence of pediatric obesity, can we expect more health problems related to the consequences of pediatric dyslipidemia, hypertriglyceridemia, and atherosclerosis in the future? For many years, medications have been available and used in adult populations to treat dyslipidemia. In recent years, reports of short-term safety of some of these medications in children have been published. However, none of these studies have detailed long-term follow-up, and therefore none have described potential late side-effects of early cholesterol-lowering therapy, or potential benefits in terms of reduction of or delay in cardiovascular or other vascular end-points. In 2007, the American Heart Association published a scientific statement on the use of cholesterol-lowering therapy in pediatric patients. In this review paper, we discuss some of the current literature on cholesterol-lowering therapy in children, including the statins that are currently available for use in children, and some of the cautions with using these and other cholesterol-lowering medications. A central tenet of this review is that medications are not a substitute for dietary and lifestyle interventions, and that even in children on cholesterol-lowering medications, physicians should take every opportunity to encourage children and their parents to make healthy diet and lifestyle choices.
Item Type:
Article
Language:
en
MeSH:
Adolescent; Biological Markers; Child; Cholesterol; Diet; Exercise; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Patient Selection; Risk Assessment; Risk Factors; Risk Reduction Behavior; Treatment Outcome
ISSN:
1178-2048

Full metadata record

DC FieldValue Language
dc.contributor.authorO'Gorman, Clodagh S Men
dc.contributor.authorO'Neill, Michael Ben
dc.contributor.authorConwell, Louise Sen
dc.date.accessioned2011-07-01T11:44:47Z-
dc.date.available2011-07-01T11:44:47Z-
dc.date.issued2010-12-
dc.identifier.citationConsidering statins for cholesterol-reduction in children if lifestyle and diet changes do not improve their health: a review of the risks and benefits. 2010, 7:1-14 Vasc Health Risk Managen
dc.identifier.issn1178-2048-
dc.identifier.pmid21339908-
dc.identifier.doi10.2147/VHRM.S7356-
dc.identifier.urihttp://hdl.handle.net/10147/135096-
dc.description.abstractChildren who appear healthy, even if they have one or more recognized cardiovascular risk factors, do not generally have outcomes of cardiovascular or other vascular disease during childhood. Historically, pediatric medicine has not aggressively screened for or treated cardiovascular risk factors in otherwise healthy children. However, studies such as the P-Day Study (Pathobiological Determinants of Atherosclerosis in Youth), and the Bogalusa Heart Study, indicate that healthy children at remarkably young ages can have evidence of significant atherosclerosis. With the increasing prevalence of pediatric obesity, can we expect more health problems related to the consequences of pediatric dyslipidemia, hypertriglyceridemia, and atherosclerosis in the future? For many years, medications have been available and used in adult populations to treat dyslipidemia. In recent years, reports of short-term safety of some of these medications in children have been published. However, none of these studies have detailed long-term follow-up, and therefore none have described potential late side-effects of early cholesterol-lowering therapy, or potential benefits in terms of reduction of or delay in cardiovascular or other vascular end-points. In 2007, the American Heart Association published a scientific statement on the use of cholesterol-lowering therapy in pediatric patients. In this review paper, we discuss some of the current literature on cholesterol-lowering therapy in children, including the statins that are currently available for use in children, and some of the cautions with using these and other cholesterol-lowering medications. A central tenet of this review is that medications are not a substitute for dietary and lifestyle interventions, and that even in children on cholesterol-lowering medications, physicians should take every opportunity to encourage children and their parents to make healthy diet and lifestyle choices.-
dc.language.isoenen
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/21339908en
dc.subject.meshAdolescent-
dc.subject.meshBiological Markers-
dc.subject.meshChild-
dc.subject.meshCholesterol-
dc.subject.meshDiet-
dc.subject.meshExercise-
dc.subject.meshHumans-
dc.subject.meshHydroxymethylglutaryl-CoA Reductase Inhibitors-
dc.subject.meshHyperlipidemias-
dc.subject.meshPatient Selection-
dc.subject.meshRisk Assessment-
dc.subject.meshRisk Factors-
dc.subject.meshRisk Reduction Behavior-
dc.subject.meshTreatment Outcome-
dc.titleConsidering statins for cholesterol-reduction in children if lifestyle and diet changes do not improve their health: a review of the risks and benefits.en
dc.typeArticleen
dc.contributor.departmentGraduate Entry Medical School, University of Limerick, Ireland, and Mid-Western Regional Hospital, Limerick, Ireland. clodagh.ogorman@ul.ieen
dc.identifier.journalVascular health and risk managementen
dc.description.provinceMunster-
All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.